Q3FY2025 Performance Highlights Revenue at ₹11,537m, grew 14.6% YoY Gross margin at ₹6,735m, grew 25.1% YoY EBITDA grew 46.9% YoY to ₹2,103m with EBITDA margin at 18.2%, grew 401bps YoY US revenue at $73m, grew 13.7% YoY Q3FY25 Reported PAT at ₹900m Reported
Fluoxetine Tabs 60 mg approval solidifies the Company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma
Strides Pharma Science Limited (Strides) today announced that it has secured the approval of its equity shareholders and secured creditors with overwhelming majority , along with those of OneSource Specialty Pharma Limited and SteriScience Specialties Private Limited, in meetings convened under the guidance of the
Q1FY2025 Performance Highlights Revenues at ₹10,875m, Grew 16.7% YoY in line with FY25 Outlook Gross Margin improved by 264bps YoY to 61.3% EBITDA grew by 28.7% YoY to ₹2,170m with EBITDA margin at 20%, a growth of 187bps YoY US revenues at a historic
FY2024 Performance Highlights Highest ever full-year Revenue of ₹40,555 million in FY24, up 14.4% YoY Highest ever full-year EBITDA of ₹7,477 million in FY24, up 77.6% YoY US business achieved top end of $250 million revenue outlook for FY24, grew by 11.8% YoY Net
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation Approval bolsters Strides’ portfolio for the US by adding another differentiated and niche product with limited competition Strides Pharma Science Limited (Strides) today announced that its step-down wholly
